Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue …
Post
-
-
WuXi debates sale of pharma operations as BIOSECURE Act advances
WuXi Biologics and WuXi AppTec are discussing the potential sale of some of their manufacturing units as the BIOSECURE Act …
-
The benefits of using a nimble platform from phase to phase
By streamlining data entry and reducing complex paperwork, digital platforms can reduce costs and timelines for clinical trials. While SaaS …
-
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on Avidity Biosciences’ investigational drug, delpacibart etedesiran …
-
NHS proposes phased launch for Eli Lilly’s Mounjaro
England’s National Health Service (NHS) has proposed a phased launch of Eli Lilly’s blockbuster weight loss drug Mounjaro (tirzepatide) because …
-
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting …
-
Teva and mAbxience partner to develop biosimilar candidate for oncology
Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein …
-
BMS receives FDA approval for Opdivo to treat NSCLC
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults …
-
Resilience secures funds to enhance production of essential medicine components
National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing. Resilience received the …
-
A rational design approach to RNA targeting could replace large-scale screening
As interest mounts in using RNA as a therapeutic target, a group at the Institute of Chemistry in Nice is …
-
Resolution scores $83m to develop macrophage cell therapies
Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based company …
-
Chronic diseases “as urgent as climate change,” says Novo Nordisk CSO
Chronic diseases such as obesity are as urgent as global warming and climate change, according to Novo Nordisk’s chief scientific …
-
Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies
Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific …
-
Healthcare Payers for the Pharmaceutical Industry
Factors such as increasing access to health information, the introduction of new medical treatments and technologies and the spike in …
-
ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer
ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with …
